Human Metabolome Technologies Joins National Cancer Institute’s OSTR Subsidy Program

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOSTON--(BUSINESS WIRE)--Human Metabolome Technologies, Inc. (HMT), the leading developer of capillary electrophoresis mass spectrometry (CE-MS) based metabolomics, has been recognized by the National Cancer Center’s Office of Science and Technology Resources (OSTR) as a preferred vendor of metabolomic services. Under this program, new technology costs are subsidized by the OSTR in an effort to advance cancer research for NCI’s Center for Cancer Research (CCR) investigators.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC